Research Topics
Genomes and GenesSpecies | Armando SantoroSummaryAffiliation: Istituto Clinico Humanitas Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: result of a dose-intensity studyHector Soto Parra
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni, 56 Rozzano Milan 20089, Italy
Invest New Drugs 25:57-62. 2007..The 3-week schedule is generally preferred because it enables better treatment compliance. To improve DI and compliance further, we delivered gemcitabine plus cisplatin over 4 days every 21 days...
Early clinical experience with volumetric modulated arc therapy in head and neck cancer patientsMarta Scorsetti
Istituto Clinico Humanitas IRCCS, Radiation Oncology Dept, Milan Rozzano, Italy
Radiat Oncol 5:93. 2010..To report about early clinical experience in radiation treatment of head and neck cancer of different sites and histology by volumetric modulated arcs with the RapidArc technology...
Large volume unresectable locally advanced non-small cell lung cancer: acute toxicity and initial outcome results with rapid arcMarta Scorsetti
Department of Radiation Oncology, IRCCS Istituto Clinico Humanitas, Milano Rozzano, Italy
Radiat Oncol 5:94. 2010..To report acute toxicity, initial outcome results and planning therapeutic parameters in radiation treatment of advanced lung cancer (stage III) with volumetric modulated arcs using RapidArc (RA)...
Oral ulcer as an exclusive sign of gastric cancer: report of a rare casePiergiuseppe Colombo
Department of Pathology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
BMC Cancer 5:117. 2005..Oral metastatic lesions have been described in various cancers, particularly lung, breast and kidney carcinoma...
LymphomasArmando Santoro
Department of Medical Oncology and Hematology, Instituto Clinico Humanitas, Rozzano-Milano, Italy
Cancer Chemother Biol Response Modif 21:399-428. 2003
Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphomaArmando Santoro
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
Haematologica 92:35-41. 2007..Results of a new induction regimen are reported in terms of response rates, toxicity, and stem cell mobilization...
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancerA Santoro
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
Ann Oncol 15:33-7. 2004..Therefore, we aimed to assess the antitumor activity and tolerability of gefitinib in a series of patients with previously treated, advanced NSCLC, as a part of a compassionate use program...
LymphomasArmando Santoro
Department of Medical Oncology and Hematology, Istituto Clnico Humanitas, Milano, Italy
Cancer Chemother Biol Response Modif 22:391-9. 2005
Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access ProgramArmando Santoro
Istituto Clinico Humanitas, Rozzano, Italy
J Thorac Oncol 3:756-63. 2008..This manuscript reports the safety and efficacy data from the nonrandomized open-label study in chemonaïve patients receiving pemetrexed plus platinum under the EAP...
Dose-escalation of CHOP in non-Hodgkin's lymphomaA Santoro
Division of Medical Oncology, Istituto Nazionale Tumori, Milano, Italy
Ann Oncol 10:519-25. 1999..In order to determine the maximum tolerable dose of an intensified CHOP regimen, a dose-escalation study of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with non-Hodgkin's lymphoma (NHL) was started...
LymphomasArmando Santoro
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Via Manzoni 56, 20089 Milan, Italy
Cancer Chemother Biol Response Modif 20:391-418. 2002
Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II studyA Santoro
Istituto Clinico Humanitas, Rozzano Milano, Italy
J Clin Oncol 18:2615-9. 2000..To explore the use of gemcitabine for the treatment of patients with relapsing or refractory Hodgkin's disease...
CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patientsElisabetta Todisco
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milano, Italy
Eur J Haematol 78:111-6. 2007..Our data suggest that G-CSF administration can be safely optimized, used only for patients infused with a suboptimal CD34(+) cell dose...
Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapyLuca Castagna
Oncology and Haematology Department, Istituto Clinico Humanitas, Rozzano MI, Italy
Br J Haematol 145:369-72. 2009..The 2-year progression-free survival was 93% vs. 10% for patients with negative and positive PET2, respectively (P < 0.001). This study shows that interim PET can predict the outcome after high-dose chemotherapy in HL patients...
Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective studyLuca Castagna
Department of Hematology and Medical Oncology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
Am J Hematol 82:122-7. 2007..Tandem HDCT is feasible and effective in patients with relapsed or refractory HL...
Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?Giuseppe Luigi Banna
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
Biol Blood Marrow Transplant 12:1085-91. 2006..Earlier HDCT administration followed by residual surgery should be considered for further investigation...
Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesotheliomaPaolo A Zucali
Department of Medical Oncology and Hematology, Humanitas Clinical Institute of Rozzano, Milan, Italy
Cancer 112:1555-61. 2008..Gemcitabine and vinorelbine have shown activity in the first-line setting. The objective of this study was to evaluate the activity and toxicity of the gemcitabine-vinorelbine combination in pemetrexed-pretreated patients with MPM...
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinomaNicola Personeni
Department of Oncology Hematology, Humanitas Cancer Center, IRCCS, Rozzano, Italy
J Hepatol 57:101-7. 2012..We investigated the prognostic usefulness of a decrease in serum alpha-fetoprotein (AFP) and compared it to RECIST...
The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II studyCarlo Carnaghi
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano Milano, Italy
Invest New Drugs 25:479-85. 2007..Extra-hepatic progression was observed in six patients. Our results suggest that this regimen is active even if technical complications are frequent. Our aim to reduce hepatic toxicity and extra-hepatic progression was reached...
Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatinPaolo Andrea Zucali
Department of Oncology, Biostatistics Unit, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy
Clin Cancer Res 17:2581-90. 2011....
Assessment of tumor response in malignant pleural mesotheliomaGiovanni L Ceresoli
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy
Cancer Treat Rev 33:533-41. 2007..New serum markers such as osteopontin and mesothelin-related proteins are under evaluation and in the future might play a role in assessing the response of MPM to treatment...
Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancerElisabetta Campagnoli
Dipartimento di Oncologia Medica e Ematologia, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, 20089, Rozzano, MI, Italy
Invest New Drugs 25:559-64. 2007..Non-haematological toxicity was mild. This schedule of cisplatin and vinorelbine treatment showed a good toxicity profile and an efficacy similar to other standard regimens. Oral vinorelbine could be administered safely at home on day 5...
Prophylaxis of central venous catheter-related thrombosis with minidose warfarin in patients treated with high-dose chemotherapy and peripheral-blood stem-cell transplantation: retrospective analysis of 228 cancer patientsMassimo Magagnoli
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
Am J Hematol 81:1-4. 2006..Four episodes of bleeding occurred, with each of these individuals having a normal INR but a platelet count below 50,000/dL. Minidose warfarin is effective and safe to use for preventing thrombotic events in this setting of patients...
Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapyCarlo Carnaghi
Department of Oncology, IRCCS Humanitas, Rozzano Milano, Italy
Nucl Med Rev Cent East Eur 10:12-5. 2007..Our aim was to assess the value of this imaging modality in the selection of patients with colorectal liver metastasis for surgery following adjuvant chemotherapy...
Short schedule of cisplatin and vinorelbine: a dose-finding study in non-small-cell lung cancerPaolo Andrea Zucali
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
Oncology 71:229-36. 2006..A dose-finding study of a new cisplatin/vinorelbine schedule was done to increase activity of the combination, and improve compliance of non-small-cell lung cancer PATIENTS...
Future developments in the management of malignant pleural mesotheliomaPaolo Andrea Zucali
Department of Medical Oncology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
Expert Rev Anticancer Ther 9:453-67. 2009..The principal goals of this review are to summarize the improvements in the management of MPM that have been achieved recently and to outline the therapeutic approaches in development...
Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusionElisabetta Todisco
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
Eur J Haematol 78:322-9. 2007..We analysed the feasibility and efficacy of allogeneic stem cell transplantation (allo-SCT) with reduced-intensity conditioning (RIC) in patients with refractory or progressive Hodgkin's disease (HD) after high-dose chemotherapy (HDCT)...
A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trialMaurizio Infante
Thoracic Surgery Department, Istituto Clinico Humanitas, Milan, Italy
Am J Respir Crit Care Med 180:445-53. 2009..Screening for lung cancer with modern imaging technology may decrease lung cancer mortality, but encouraging results have only been obtained in uncontrolled studies...
Assessment of prognostic factors in patients with metastatic epidural spinal cord compression (MESCC) from solid tumor after surgery plus radiotherapy: a single institution experienceFlavio Tancioni
Department of Neurosurgery, Istituto Clinico Humanitas, Rozzano, Italy
Eur Spine J 21:S146-8. 2012..To identify potential prognostic factors predicting functional outcome and survival after surgery followed by radiotherapy for metastatic spinal cord compression due to solid tumors...
Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphomaLuca Castagna
Hematology Oncology Department, Istituto Clinico Humanitas, Rozzano, Milano, Italy
Biol Blood Marrow Transplant 15:432-8. 2009..The 1-year nonrelapse mortality (NRM) in the ALLO group was 8% versus 0% in the CHEMO group. This study, suggests that allogeneic transplantation may prolong the survival in patients with a poor-risk HD...
Volumetric modulation arc radiotherapy compared with static gantry intensity-modulated radiotherapy for malignant pleural mesothelioma tumor: a feasibility studyMarta Scorsetti
Department of Radiation Oncology, Istituto Clinico Humanitas, Rozzano, Italy
Int J Radiat Oncol Biol Phys 77:942-9. 2010..A planning study was performed to evaluate RapidArc (RA), a volumetric modulated arc technique, on malignant pleural mesothelioma. The benchmark was conventional fixed-field intensity-modulated radiotherapy (IMRT)...
Primary mediastinal B-cell lymphoma with sclerosis: report of 11 cases treated with intensified-CHOP plus radiotherapyLicia Siracusano
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
Am J Hematol 78:312-3. 2005..After a median follow up of 30 months, all patients but one are in continuous complete remission (CR), and overall survival is 100%...
Multimodal approach to the management of metastatic epidural spinal cord compression (MESCC) due to solid tumorsFlavio Tancioni
Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy
Int J Radiat Oncol Biol Phys 78:1467-73. 2010..To assess the impact of a multidisciplinary approach for treatment of patients with metastatic epidural spinal cord compression in terms of feasibility, local control, and survival...
Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implicationsS Viviani
Division of Medical Oncology A, Istituto Nazionale Tumori, Milano, Italy
Br J Cancer 77:992-7. 1998....
Surgery followed by radiotherapy for the treatment of metastatic epidural spinal cord compression from breast cancerFlavio Tancioni
Department of Neuro Surgery, IRCCS Istituto Clinico Humanitas, Rozzano, Italy
Spine (Phila Pa 1976) 36:E1352-9. 2011..Retrospective analysis of breast cancer patients with metastatic epidural spinal cord compression (MESCC) undergoing surgery and radiation therapy...
Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): safety, efficacy, and complicationsGiovanna Masci
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089, Rozzano, Milano, Italy
Support Care Cancer 14:1141-6. 2006..This study is a retrospective investigation of our experience using the Vygon catheter as a long-term CVC in patients with malignancy...
Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-upAnnarita Destro
Molecular Genetics Laboratory, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, 20089 Rozzano, Milan, Italy
Lung Cancer 59:369-76. 2008..This result suggests the need to select homogeneously treated and staged patients with MPM to address whether their methylation profile may impact on patient's survival...
Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availabilityBarbara Sarina
Hematology Department, Istituto Clinico Humanitas, Milano, Italy
Blood 115:3671-7. 2010..001). Patients allografted in complete remission showed a better PFS and OS. This is the largest study comparing RIC alloSCT versus conventional treatment after a failed autoSCT, indicating a survival benefit for patients having a donor...
Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancerGiuseppe Gullo
Oncology and Hematology Unit, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, Rozzano, Milan, Italy
Invest New Drugs 27:179-83. 2009..If confirmed in larger cohorts of patients, HER2/CEP17 ratio could represent a reliable and economical predictor of response to trastuzumab-based therapy in MBC...
Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institutionMassimo Magagnoli
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano Milan, Italy
Am J Hematol 73:267-72. 2003..HDT supported by PBSC is a feasible procedure in selected elderly patients, and an age of more than 60 years should not be considered a contraindication for HDT...
Early surgical experience with minimally invasive percutaneous approach for patients with metastatic epidural spinal cord compression (MESCC) to poor prognosesFlavio Tancioni
Department of Neurosurgery, Istituto Clinico Humanitas Cancer Center, Milan, Italy
Ann Surg Oncol 19:294-300. 2012....
Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumorsFrancesco Sclafani
Medical Oncology and Hematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, IRCCS, Rozzano MI, Italy
Tumori 97:620-8. 2011..Immunohistochemistry (IHC) was reported as a reliable method for the detection of SSTRs with theoretically superior sensitivity over SRS...
Prophylaxis of central venous catheter-related thrombosis with minidose warfarin: analysis of its use in 427 cancer patientsMassimo Magagnoli
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
Anticancer Res 25:3143-7. 2005....
High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective studyAlexia Bertuzzi
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
J Clin Oncol 20:2181-8. 2002..In this phase II study, we explored a high-dose chemotherapy (HD-CT) approach and analyzed the clinical significance of fusion transcripts detection...
Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastasesMario Bignardi
Radiation Oncology Department, IRCCS Istituto Clinico Humanitas, Rozzano, Italy
Int J Radiat Oncol Biol Phys 81:831-8. 2011..We report the medium-term clinical outcome of hypofractionated stereotactic body radiotherapy (SBRT) in a series of patients with either a solitary metastasis or oligometastases from different tumors to abdominal lymph nodes...
Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucoseGiovanni L Ceresoli
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy
J Clin Oncol 24:4587-93. 2006..There is growing evidence that therapy-induced changes in tumor [(18)F]fluorodeoxyglucose (FDG) uptake as measured by positron emission tomography (PET) may predict response and patient outcome early in the course of treatment...
Rectal squamous cell carcinoma treated with chemoradiotherapy: report of six casesMaria Chiara Tronconi
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089, Rozzano, Milan, Italy
Int J Colorectal Dis 25:1435-9. 2010..A retrospective analysis of these cases was performed in order to evaluate the role of chemoradiotherapy as an alternative to surgery...
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitorsP A Zucali
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
Ann Oncol 19:1605-12. 2008..However, resistance mechanisms are not well understood. We evaluated several potential biological markers of intrinsic EGFR-TKIs-resistance in NSCLC...
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancerH S Parra
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via A Manzoni 56, Rozzano, Milan 20089, Italy
Br J Cancer 91:208-12. 2004..Gefitinib demonstrated promising clinical activity in this group of patients with NSCLC. These results have also shown that EGFR expression is not a significant predictive factor for response to gefitinib...
Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature reviewMarta Scorsetti
Department of Radiotherapy and Radiosurgery, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy
Tumori 98:67e-71e. 2012..We discuss the case comparing our approach with other experiences reported in the literature...
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapyArmando Santoro
Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy
Eur J Cancer 46:2746-52. 2010..Preclinical antitumour activity was observed even at low doses. We evaluated the activity and safety of low-dose NGR-hTNF in colorectal cancer (CRC) patients failing standard therapies...
Vertebroplasty for pain relief and spinal stabilization in multiple myelomaFlavio Tancioni
Department of Neurosurgery, Instituto Clinico Humanitas, Milan, Italy
Neurol Sci 31:151-7. 2010....
What is the best option to cure patients with resistant/relapsing Hodgkin's disease?Massimo Magagnoli
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
Curr Stem Cell Res Ther 1:419-24. 2006..In this review we analyzed the results of the most important salvage chemotherapy combinations as well as allogeneic transplantations to clarify the optimal treatment options for patients with resistant/relapsing HD...
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesotheliomaVanesa Gregorc
Department of Oncology, Istituto Scientifico San Raffaele, Universita Vita Salute San Raffaele, Milan, Italy
J Clin Oncol 28:2604-11. 2010..Currently, there are no standard options for patients with MPM who are failing a front-line pemetrexed-based regimen. We explored safety and efficacy of NGR-hTNF in this setting...
Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatmentsMarta Scorsetti
Radiotherapy and Radiosurgery, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Milano, Italy
Radiat Oncol 7:145. 2012..To report results in terms of feasibility and early toxicity of hypofractionated simultaneous integrated boost (SIB) approach with Volumetric Modulated Arc Therapy (VMAT) as adjuvant treatment after breast-conserving surgery...
Neutropenic enterocolitis: is there a right timing for surgery? Assessment of a clinical casePietro Bagnoli
Department of Surgical Oncology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
Tumori 93:608-10. 2007....
Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenibGiovanni Abbadessa
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, 20089 Rozzano, Milan, Italy
World J Gastroenterol 17:2450-3. 2011..This report supports the feasibility of dose adjustments to allow prolonged administration of sorafenib, and highlights the need for new imaging criteria for a more appropriate characterization of response in HCC...
Retroperitoneal sarcoma: is it time to change the surgical policy?Chiara Mussi
Sarcoma Unit, Surgical Department, Istituto Clinico Humanitas, University of Milan School of Medicine, Rozzano Milan, Italy
Ann Surg Oncol 18:2136-42. 2011..We analyzed a single-institution series of RPS to provide information useful to surgical decision-making...
Percutaneous vertebral augmentation in metastatic disease: state of the artFlavio Tancioni
Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy
J Support Oncol 9:4-10. 2011....
The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomasPaolo Andrea Zucali
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni, 56 Rozzano, Milan, 20089, Italy
Invest New Drugs 26:175-81. 2008....
Case report of acute aortic dissection during treatment with capecitabine for a late recurrence of breast cancerFrancesco Sclafani
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, IRCCS, Rozzano, Italy
Chemotherapy 56:203-7. 2010..Moreover, the potential association between anticancer drugs and vascular damage is well known since chemotherapeutics, such as fluoropyrimidines, were introduced into clinical practice...
Herpes infections in breast cancer patients treated with adjuvant chemotherapyGiovanna Masci
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Milan, Italy
Oncology 71:164-7. 2006..The aim of this study is to evaluate the incidence of Herpes zoster and simplex infections in this patients setting...
Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastasesElena Miranda
Molecular Genetics Laboratory, Humanitas Clinical and Research Center, Milan, Italy
Cancer 119:266-76. 2013..The objective of this study was to evaluate the presence of molecular heterogeneity during metastatic progression and its potential impact on clinical treatment...
High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical reviewGiuseppe Luigi Banna
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni, 56, 20089 Rozzano, Milano, Italy
Curr Stem Cell Res Ther 2:65-82. 2007..Well-designed randomized studies and future strategies integrating HDCT with concomitant and/or subsequent anti-tumor therapies targeted against the residual disease might be suggested in clinically and biologically selected patients...
Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomasElisa Stroppa
Department of Medical Oncology and Haematology, Istituto Clinico Humanitas, Via Manzoni 56, Rozzano, Milan, 20089, Italy
Invest New Drugs 28:834-8. 2010..The aim of this study was to evaluate the maximum tolerated dose (MTD) and safety of the combination of non- pegylated liposomal doxorubicin (Myocet) and ifosfamide in patients with metastatic soft tissue sarcomas...
CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal studyLuigi Laghi
Laboratories of Molecular Gastroenterology, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy
Lancet Oncol 10:877-84. 2009..The aim of this study was to assess the relationship between the density of CD3+ TIL and the postsurgical occurrence of distant-organ metastases in a large series of patients with deeply invading and MSI-typed colorectal cancer...
Phase II study of pemetrexed plus carboplatin in malignant pleural mesotheliomaGiovanni L Ceresoli
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico, Rozzano, Milan, Italy
J Clin Oncol 24:1443-8. 2006..This multicenter, phase II clinical study was conducted to evaluate the activity of the combination of pemetrexed and carboplatin in patients with malignant pleural mesothelioma (MPM)...
Combined systemic and intrathecal chemotherapy plus radiotherapy in testicular lymphoma: a report of two casesMassimo Magagnoli
Departmenti of Medical Oncology and Hematology, Istituto Clinico Humanitas- Via Manzoni 56, 20089 Rozzano, Italy
Haematologica 87:ELT22. 2002
Metastasis of hepatocellular carcinoma to the heart: a case report and review of the literatureGiovanna Masci
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
Tumori 90:345-7. 2004..The patient died of progressive hepatic failure six months later. In addition to this case report, a review of the literature on heart involvement from HCC is presented...
The present and the future landscape of treatment of advanced hepatocellular carcinomaLorenza Rimassa
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
Dig Liver Dis 42:S273-80. 2010..In this review, we will summarize the data concerning the present standard treatment for advanced HCC and discuss the newest, most promising clinical research that may affect the future treatment of this disease...
Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized studyC Tondini
Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
Ann Oncol 11:231-3. 2000..It is unclear whether the purine analogs fludarabine (Flu) and cladribine (CdA) are non-resistant...
Irinotecan and raltitrexed: an active combination in advanced colorectal cancerC Carnaghi
Medical Oncology and Haematology Department, Istituto Clinico Humanitas, Milan, Italy
Ann Oncol 13:1424-9. 2002..CONCLUSIONS: Results achieved with irinotecan and raltitrexed show that this regimen is active, despite 'not-negligible' toxicity, and may represent a useful regimen for specific subgroups of colorectal cancer patients...
High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acidMonica Zuradelli
Dipartimento di Oncologia Medica ed Ematologia, Istituto Clinico Humanitas, Via Manzoni 56, Rozzano, Milan, Italy
Oncologist 14:548-56. 2009..The primary aim of this study was to establish the actual incidence of hypocalcemia and serum creatinine elevation during treatment with zoledronic acid. Skeletal-related events and side effects were also assessed...
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trialLorenza Rimassa
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
Expert Rev Anticancer Ther 9:739-45. 2009..The SHARP trial has demonstrated that sorafenib is effective in prolonging median survival and time-to-progression in patients with advanced HCC and that it is generally well tolerated with a manageable adverse events profile...
Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancerLorenza Rimassa
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano MI, Italy
Breast Cancer Res Treat 77:185-8. 2003..Toxicity was acceptable, however, grade 3-4 neutropenia was not negligible. Our study does not support the development of this combination in advanced breast cancer...
Role of computed tomography and [18F] fluorodeoxyglucose positron emission tomography image fusion in conformal radiotherapy of non-small cell lung cancer: a comparison with standard techniques with and without elective nodal irradiationGiovanni Luca Ceresoli
Department of Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
Tumori 93:88-96. 2007....
Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatinLorenza Rimassa
Medical Oncology and Haematology Department, Istituto Clinico Humanitas, Rozzano, MI, Italy
Tumori 92:285-9. 2006..To assess the activity and tolerability of the combination of mitomycin C and capecitabine in patients with metastatic colorectal cancer after failure of irinotecan and oxaliplatin-containing regimens...
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II studyP F Conte
Department of Medical Oncology and Hematology, University of Modena and Reggio Emilia, Italy
Br J Cancer 93:406-11. 2005..The gemcitabine, epirubicin, taxol regimen is active and well tolerated as PCT for operable breast cancer. This combination allows the administration of full doses of active agents with a low incidence of febrile neutropenia...
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)Federico Cappuzzo
Division of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139 Bologna, Italy
Lung Cancer 41:227-31. 2003..We report four cases of Brain Metastases (BM) from non-small cell lung cancer (NSCLC) responding to ZD 1839 therapy after standard therapy failure...
Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomasL Castagna
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
Bone Marrow Transplant 30:207-14. 2002..Our study confirms that a low intensity conditioning regimen for allogeneic stem cell transplantation is feasible and effective in heavily pretreated patients...
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patientsFederico Cappuzzo
Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico, Department of Oncology Hematology, University of Milan School of Medicine, IRCCS Istituto Clinico Humanitas, Rozzano, Italy
J Clin Oncol 27:1667-74. 2009..To investigate the prognostic role of genomic gain for MET and epidermal growth factor receptor (EGFR) genes in surgically resected non-small-cell lung cancer (NSCLC)...
Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristicsMonica Zuradelli
Unit of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
Breast Cancer Res Treat 124:251-8. 2010..The possible association of DH for BRCA gene mutations with gastrointestinal tumors is in keeping with previous reports, but needs to be confirmed by further analyses...
Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancerRosalba Torrisi
Research Unit of Medical Senology at the Department of Medicine, European Institute of Oncology, Milano, Italy
Breast Cancer Res Treat 126:431-41. 2011....
Isolated massive meningeal progression in aggressive non Hodgkin's lymphomaMassimo Magagnoli
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas- Via Manzoni 56, 20089 Rozzano (Milano)-Italy
Haematologica 87:EIM15. 2002
Solitary plasmacytoma of the duodenumMassimo Magagnoli
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
Am J Hematol 76:185-6. 2004
Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancerAlberto Malesci
Department of Gastroenterology, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy
Clin Cancer Res 13:3831-9. 2007..Although associated with earlier-stage tumors, MSI has been proposed as an independent predictor of survival. We tested the prognostic value of MSI in a large series of patients diagnosed with colorectal cancer in the last decade...
Cardiac involvement in non-Hodgkin's lymphomaMassimo Magagnoli
Department of Medical Oncology and Haematology, Department of Radiology, Istituto Clinico Humanitas, Rozzano (Milan, Italy
Br J Haematol 119:887. 2002
Re-irradiation of metastatic spinal cord compression: a feasibility study by volumetric-modulated arc radiotherapy for in-field recurrence creating a dosimetric hole on the central canalPietro Mancosu
IRCCS Istituto Clinico Humanitas, Radiation Oncology, Via Manzoni 56, 20098 Rozzano, Italy
Radiother Oncol 94:67-70. 2010..A clinically satisfactory PTV coverage and dose sparing to the spinal cord were obtained. An upcoming trial on patients will provide clinical outcomes...
Lung cancer screening with spiral CT: baseline results of the randomized DANTE trialMaurizio Infante
Thoracic Surgery Department, Istituto Clinico Humanitas, Rozzano, Milano, Italy
Lung Cancer 59:355-63. 2008..We herewith present the baseline results of a randomized trial comparing screening for lung cancer with annual spiral computed tomography (CT) versus a yearly clinical review...
Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy?Giovanna Masci
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
J Clin Oncol 21:736-9. 2003..We analyzed the incidence of alterations in the International Normalized Ratio (INR) and bleeding in cancer patients given minidose warfarin during treatment with continuous-infusion FU-based regimens...
Multidisciplinary treatment of malignant pleural mesotheliomaGiovanni Luca Ceresoli
Dipartimento di Oncologia Medica e Ematologia, Istituto Clinico Humanitas IRCCS, Via Manzoni, Rozzano MI, Italy
Oncologist 12:850-63. 2007..However, currently available treatments still appear to have modest results. Further studies are needed to provide evidence-based recommendations for the treatment of early and advanced stages of this disease...
Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagusPaolo Bidoli
Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Cancer 94:352-61. 2002..The authors performed a prospective, Phase II study to assess the long-term results of chemotherapy plus radiotherapy (RT) on patients with esophageal squamous cell carcinoma...
Sinusal localization of nodal micrometastases is a prognostic factor in breast cancerG Masci
Department of Oncology and Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy
Ann Oncol 21:1228-32. 2010..Material and methods: We retrospectively investigated the outcome of 122 patients with nodal micrometastases from breast cancer followed up for 60 months...
Outcome of T1N0M0 breast cancer in relation to St. Gallen risk assignment criteria for adjuvant therapyI Garassino
Department of Oncology and Hematology, Istituto Clinico Humanitas IRCCS, 20089 Rozzano Milano, Italy
Breast 18:263-6. 2009....
Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patientsF Cappuzzo
Department of Oncology Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico IRCCS, Rozzano
Ann Oncol 21:562-7. 2010..Patients exposed to anti-epidermal growth factor receptor (EGFR) agents were excluded. IGF1R expression was evaluated by immunohistochemistry in tissue microarray sections...
Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remissionS Viviani
Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
Ann Oncol 1:123-7. 1990..Present findings indicate that about half of patients relapsing after a disease-free interval exceeding 12 months can remain alive and disease-free 5 years after starting salvage chemotherapy...
IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patientsM Magagnoli
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
Bone Marrow Transplant 40:1019-25. 2007..Thirty-four patients received a single and 47 received tandem transplantation with rapid engraftment. These results confirm that the IGEV regimen with lenograstim support can be used successfully and safely to mobilize PBSCs...
Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challengesF Cappuzzo
Department of Oncology Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy
Int J Biol Markers 22:S10-23. 2007....
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patientsF Cappuzzo
Department of Medical Oncology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy
Ann Oncol 19:717-23. 2008..Results were analyzed according to different score systems previously reported in colorectal and lung cancers. The primary end point of the study was identification of the EGFR FISH score that best associates with response rate (RR)...
[Angiosarcoma of the nasal cavity. Report of a case and review of the literature]L Di Tommaso
Department of Pathology, School of Medicine University of Milan, Humanitas Clinical Institute, Rozzano, Milan, Italy
Pathologica 99:76-80. 2007....
Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II studyH Soto Parra
Department of Medical Oncology and Hematology and Division of Thoracic Surgery, Istituto Clinico Humanitas, Rozzano Milan, Italy
Ann Oncol 13:1080-6. 2002..We therefore started a randomized phase II trial to compare toxicity and dose intensity (DI) between these two GC schedules...
